Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cethrin in acute spinal cord injury
NCT00500812Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2005
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of cethrin in spinal cord injury (SCI) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and Tolerability of Cethrin at 12 months and Pharmacokinetics of Cethrin at 12 months. Started Feb 2005; status: completed.
02
Drugs
cethrin
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT00500812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500812.